NCT00141167View on ClinicalTrials.gov

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

February 28, 2005

Study Completion Date

January 31, 2006

Conditions
Smoking Cessation
Interventions
DRUG

varenicline

Trial Locations (10)

100

Pfizer Investigational Site, Taipei

333

Pfizer Investigational Site, Kweishan

813

Pfizer Investigational Site, Kaohsiung City

970

Pfizer Investigational Site, Hualien City

40705

Pfizer Investigational Site, Taichung

431-070

Pfizer Investigational Site, Anyang-si

700-712

Pfizer Investigational Site, Daegu

100-032

Pfizer Investigational Site, Seoul

110-744

Pfizer Investigational Site, Seoul

138-736

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00141167 - A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation | Biotech Hunter | Biotech Hunter